Eisai Aricept ODT Patent Infringement Suit Triggers 30-Month Stay
This article was originally published in The Pink Sheet Daily
Eisai filed a patent infringement lawsuit against Mutual Pharmaceuticals and United Research Laboratories in Newark, N.J. district court Aug. 3, triggering a 30-month stay of FDA action on the firms' pending ANDA for a generic version of the Alzheimer's disease medication Aricept Orally Disintegrating Tablets (donepezil hydrochloride)
You may also be interested in...
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.